362670-06-2

Basic information

• Product Name: tert-Butyl 5-fluoro-2-nitrophenylcarbamate
• Synonyms: tert-Butyl 5-fluoro-2-nitrophenylcarbamate;tert-butyl N-(5-fluoro-2-nitrophenyl)carbamate;(5-Fluoro-2-nitro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 362670-06-2
• Molecular Formula: C₁₁H₁₃FN₂O₄
• Molecular Weight: 256.2303232
• Mol File: 362670-06-2.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 5-fluoro-2-nitrophenylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 5-fluoro-2-nitrophenylcarbamate(362670-06-2)
• EPA Substance Registry System: tert-Butyl 5-fluoro-2-nitrophenylcarbamate(362670-06-2)

Safety Data

• Hazardous Substances Data: 362670-06-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H13FN2O4/c1-11(2,3)18-10(15)13-8-6-7(12)4-5-9(8)14(16)17/h4-6H,1-3H3,(H,13,15)

Upstream product

• 320-98-9 5-fluoro-2-nitrobenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2369-11-1 5-fluoro-2-nitroaniline 

Downstream Products

• 849236-19-7 tert-butyl 2-nitro-5-(thiophen-2-ylthio)phenylcarbamate 
• 362670-07-3 (2-amino-5-fluorophenyl)carbamic acid tert-butyl ester 
• 348133-45-9 6-fluoro-1-methyl-1,3-dihydro-2H-benzimidazol-2-one 

Relevant articles and documents

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors

Currently, synergistic inhibition of poly(ADP-ribose) polymerase-1 (PARP-1) and histone deacetylases (HDACs) has been a potential effective strategy for cancer treatment. Herein, by combining critical pharmacophores in approved drugs olaparib and chidamid

1,3-dioxo-isoindoline benzamide compound and application thereof

The invention belongs to the technical field of diabetes treatment medicines and in particular relates to an N-(2-aminophenyl)-3-(1,3-dioxo-isoindoline-2-yl) benzamide compound, and a preparation andapplication thereof in preparing diabetes treatment medicines. The compound has a formula (1) shown in the description, in the formula, R is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, and X is selected from hydrogen or fluorine. The N-(2-aminophenyl)-3-(1,3-dioxo-isoindoline-2-yl) benzamide compound has a remarkable function of protecting pancreatic beta cells, and can be adopted to prepare novel diabetes treatment medicines.